13 results
424B3
SHPH
Shuttle Pharmaceuticals Holdings Inc
22 Mar 24
Prospectus supplement
6:07am
incorporation of the TdR analogs. As such, high-grade brain tumors are ideal targets for this approach to radiation sensitization. In Phase I/Phase II clinical … in having two active catalytic domains and a unique physiological function. In addition to the modification of histones, HDAC6 targets specific substrates
424B3
SHPH
Shuttle Pharmaceuticals Holdings Inc
24 Aug 23
Prospectus supplement
2:00pm
. As such, high-grade brain tumors are ideal targets for this approach to radiation sensitization. In Phase I/Phase II clinical trials, prolonged survival … to the modification of histones, HDAC6 targets specific substrates including α-tubulin and HSP90, and are involved in protein trafficking and degradation, cell
DRS
SHPH
Shuttle Pharmaceuticals Holdings Inc
29 Sep 22
Draft registration statement
12:00am
targets for this approach to radiation sensitization. In Phase I/Phase II clinical trials, prolonged survival outcomes were observed compared to RT … catalytic domains and a unique physiological function. In addition to the modification of histones, HDAC6 targets specific substrates including α-tubulin
424B4
SHPH
Shuttle Pharmaceuticals Holdings Inc
31 Aug 22
Prospectus supplement with pricing info
6:16am
normal brain tissues that show little to no DNA incorporation of the TdR analogs. As such, high-grade brain tumors are ideal targets … and a unique physiological function. In addition to the modification of histones, HDAC6 targets specific substrates including α-tubulin and HSP90
S-1/A
9kg 0x8bimf30
23 Jun 22
IPO registration (amended)
5:24pm
S-1
rz1dmbrg
3 Jun 22
IPO registration
5:32pm
DRS/A
m67iqi
26 Apr 22
Draft registration statement (amended)
12:00am
DRS
9rba6f
16 Sep 19
Draft registration statement
12:00am
- Prev
- 1
- Next